Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 131

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 131
---
 as specified in the Sales Agreement, to terminate the Sales Agreement at each party’s sole discretion at any time. The offering of the ADSs pursuant to the
Sales Agreement will otherwise terminate upon the termination of the Sales Agreement as provided therein.

The
compensation payable to the Sales Agent will be an amount of up to 3.0% of the gross proceeds of any ADSs sold through it pursuant to the Sales Agreement and we will reimburse the Sales Agent for certain expenses, including fees and disbursements of
legal counsel. In accordance with Financial Industry Regulatory Authority, Inc. Rule 5110, these reimbursed fees and expenses are deemed sales compensation to the Sales Agent in connection with this offering. We estimate that the total expenses of
the offering payable by us, excluding compensation payable to the Sales Agent under the Sales Agreement, will be approximately $250,000.

The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental,
regulatory or self-regulatory organization in connection with the sales of the ADSs, will equal our net proceeds for the sale of such ADSs.

The Sales Agent will provide written confirmation to us no later than the next succeeding trading day on the Nasdaq Global
Market after each such day on which ADSs are sold under the Sales Agreement. Each confirmation will include the amount or number of ADSs sold on that day, the volume-weighted average price of the ADSs sold, the percentage of the daily trading volume
and the net proceeds to us from such sales.

Settlement for sales of ADSs will occur, unless the parties agree otherwise,
on the first trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. We will report at least biannually
the number of ADSs sold through the Sales Agent under the Sales Agreement, the net proceeds to us and the compensation paid by us to the Sales Agent in connection with the sales of shares of ADSs during the relevant period.

In connection with the sale of the ADSs on our behalf pursuant to the Sales Agreement, the Sales Agent will be deemed to be an
“underwriter” within the meaning of the Securities Act and the compensation paid to the Sales Agent will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and
contribution to the Sales Agent with respect to certain liabilities, including liabilities